Aging bone marrow accumulates cytotoxic CD4+ T cells that produce CCL5, driving age-associated changes in blood cell production through CCR5 signaling. Blocking this pathway reverses the process and extends healthspan in aged mice, suggesting a mechanistic target for age-related immune and hematopoietic dysfunction.
Key Points
- Cytotoxic CD4+ T cells accumulate in aging bone marrow via CCL5 production
- CCL5–CCR5 signaling axis drives pathological myelopoiesis during aging
- CCR5 blockade reverses aging effects and improves healthspan in mice
Longevity Analysis
This research identifies a specific molecular brake on healthy bone marrow function during aging. The bone marrow's ability to produce balanced blood cells—critical for both immune defense and energy production—deteriorates through a signaling pathway that can be pharmacologically interrupted. The finding that CCR5 blockade not only reverses this axis but improves overall healthspan suggests that age-related immune dysregulation in the marrow is not inevitable; it is a targetable process. This opens a pathway for interventions that restore the marrow's regenerative capacity rather than merely manage downstream consequences of aging.
Original published by Nature Aging, by Enrique Gabandé-Rodríguez.